Dual loss of Rb1 and Trp53 in the adrenal medulla leads to spontaneous pheochromocytoma

Neoplasia

Volumn 12, Issue 3, 2010, Pages 235-243

  Tonks, Ian D ^a   Mould, Arne W ^a   Schroder, Wayne A ^a   Cotterill, Andrew ^b   Hayward, Nicholas K ^a   Walker, Graeme J ^a   Kay, Graham F ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b MATER CHILDREN S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CATECHOLAMINE; PROTEIN; PROTEIN P107; PROTEIN P130; TRP53 PROTEIN; UNCLASSIFIED DRUG;

ADRENAL MEDULLA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CHROMAFFIN CELL; ELECTRON MICROSCOPY; EMBRYO DEVELOPMENT; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; GENE DELETION; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MORTALITY; MOUSE; NEURAL CREST; NONHUMAN; PHENOTYPE; PHEOCHROMOCYTOMA; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN DEPLETION; TUMOR SUPPRESSOR GENE;

EID: 77949574182     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91646     Document Type: Article

References (55)

1. Cheng M, Olivier P, Diehl JA, Fero M, Roussel MF, Roberts JM, and Sherr CJ (1999). The p21(Cip1) and p27(Kip1) CDK "inhibitors" are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18, 1571-1583.
2. 1-phase progression. Genes Dev 13, 1501-1512.
3. Jiang H, Chou HS, and Zhu L (1998). Requirement of cyclin E-Cdk2 inhibition in p16(INK4a)-mediated growth suppression. Mol Cell Biol 18, 5284-5290.
4. 1. Cancer Res 59, 2577-2580.
5. INK4A promoter is associated with malignant behavior in abdominal extra-adrenal paragangliomas but not pheochromocytomas. Endocr Relat Cancer 15, 609-621.
6. Franklin DS, Godfrey VL, O'Brien DA, Deng C, and Xiong Y (2000). Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 20, 6147-6158.
7. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R, Chin L, and DePinho RA (2002). Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci USA 99, 1455-1460.
8. Schraml P, Bucher C, Bissig H, Nocito A, Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, et al. (2003). Cyclin E overexpression and amplification in human tumours. J Pathol 200, 375-382.
9. Helin K, Holm K, Niebuhr A, Eiberg H, Tommerup N, Hougaard S, Poulsen HS, Spang-Thomsen M, and Norgaard P (1997). Loss of the retinoblastoma protein-related p130 protein in small cell lung carcinoma. Proc Natl Acad Sci USA 94, 6933-6938.
10. Cinti C, Claudio PP, Howard CM, Neri LM, Fu Y, Leoncini L, Tosi GM, Maraldi NM, and Giordano A (2000). Genetic alterations disrupting the nuclear localization of the retinoblastoma-related gene RB2/p130 in human tumor cell lines and primary tumors. Cancer Res 60, 383-389.
11. Claudio PP, Howard CM, Pacilio C, Cinti C, Romano G, Minimo C, Maraldi NM, Minna JD, Gelbert L, Leoncini L, et al. (2000). Mutations in the retinoblastoma-related gene RB2/p130 in lung tumors and suppression of tumor growth in vivo by retrovirus-mediated gene transfer. Cancer Res 60, 372-382.
12. Robanus-Maandag E, Dekker M, van der Valk M, Carrozza ML, Jeanny JC, Dannenberg JH, Berns A, and te Riele H (1998). p107 is a suppressor of retinoblastoma development in pRb-deficient mice. Genes Dev 12, 1599-1609.
13. Dannenberg JH, Schuijff L, Dekker M, van der Valk M, and Riele HT (2004). Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 18, 2952-2962.
14. Tonks ID, Hayward NK, and Kay GF (2006). Pocket protein function in melanocyte homeostasis and neoplasia. Pigment Cell Res 19, 260-283.
15. Classon M, Kennedy BK, Mulloy R, and Harlow E (2000). Opposing roles of pRB and p107 in adipocyte differentiation. Proc Natl Acad Sci USA 97, 10826-10831.
16. Carnac G, Fajas L, L'Honore A, Sardet C, Lamb NJ, and Fernandez A (2000). The retinoblastoma-like protein p130 is involved in the determination of reserve cells in differentiating myoblasts. Curr Biol 10, 543-546.
17. MacPherson D, Sage J, Crowley D, Trumpp A, Bronson RT, and Jacks T (2003). Conditional mutation of Rb causes cell cycle defects without apoptosis in the central nervous system. Mol Cell Biol 23, 1044-1053.
18. Nikitin AY, Juarez-Perez MI, Li S, Huang L, and Lee WH (1999). RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. Proc Natl Acad Sci USA 96, 3916-3921.
19. Williams BO, Schmitt EM, Remington L, Bronson RT, Albert DM, Weinberg RA, and Jacks T (1994). Extensive contribution of Rb-deficient cells to adult chimeric mice with limited histopathological consequences. EMBO J 13, 4251-4259.
20. Longeart LE (1996). Jones TC, Capen CC, and Mohr U (1996). Adrenal medullary tumours, mouse. Monographs on Pathology of Laboratory Animals. Endocrine System Berlin, Germany: Springer-Verlag, 421-427.
21. Lam KY, Lo CY, Wat NM, Luk JM, and Lam KS (2001). The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas. J Clin Pathol 54, 443-448.
22. Dannenberg JH, Schuijff L, Dekker M, van der Valk M, and te Riele H (2004). Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. Genes Dev 18, 2952-2962.
23. -/- mice are normal in vivo but exhibit proliferation and pigmentation defects in vitro. Pigment Cell Res 18, 252-264.
24. Tonks ID, Nurcombe V, Paterson C, Zournazi A, Prather C, Mould AW, and Kay GF (2003). Tyrosinase-Cre mice for tissue-specific gene ablation in neural crest and neuroepithelial-derived tissues. Genesis 37, 131-138.
25. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, and Berns A (2001). Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 29, 418-425.
26. Walker GJ, Kimlin MG, Hacker E, Ravishankar S, Muller HK, Beermann F, and Hayward NK (2009). Murine neonatal melanocytes exhibit a heightened proliferative response to ultraviolet radiation and migrate to the epidermal basal layer. J Invest Dermatol 129, 184-193.
27. Allan DJ, Gobe GC, and Harmon BV (1988). Sertoli cell death by apoptosis in the immature rat testis following x-irradiation. Scanning Microsc 2, 503-512.
28. De la Torre JC (1980). An improved approach to histofluorescence using the SPG method for tissue monoamines. J Neurosci Methods 3, 1-5.
29. Tonks ID, Mould A, Nurcombe V, Cool SM, Walker GJ, Hacker E, Keith P, Schroder WA, Cotterill A, Hayward NK, et al. (2009). Dual loss of Rb1 and Trp53 in melanocytes perturbs melanocyte homeostasis and genetic stability in vitro but does not cause melanoma or pigmentation defects in vivo. Pigment Cell Melanoma Res 22, 328-330.
30. Jones GN, Tep C, Towns WH II, Mihai G, Tonks ID, Kay GF, Schmalbrock PM, Stemmer-Rachamimov AO, Yoon SO, and Kirschner LS (2008). Tissuespecific ablation of Prkar1a causes schwannomas by suppressing neurofibromatosis protein production. Neoplasia 10, 1213-1221.
31. Hoffman BB (1991). Adrenergic pharmacology in rats harboring pheochromocytoma. Hypertension 18, III35-III39.
32. Gimm O (2005). Pheochromocytoma-associated syndromes: genes, proteins and functions of RET, VHL and SDHx. Fam Cancer 4, 17-23.
33. Melicow MM (1977). One hundred cases of pheochromocytoma (107 tumors) at the Columbia-Presbyterian Medical Center, 1926-1976: a clinicopathological analysis. Cancer 40, 1987-2004.
34. Proye C, Vix M, Goropoulos A, Kerlo P, and Lecomte-Houcke M (1992). High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest 15, 651-663.
35. Mannelli M, Simi L, Gagliano MS, Opocher G, Ercolino T, Becherini L, and Parenti G (2007). Genetics and biology of pheochromocytoma. Exp Clin Endocrinol Diabetes 115, 160-165.
36. Bai F, Pei XH, Pandolfi PP, and Xiong Y (2006). p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. Mol Cell Biol 26, 4564-4576.
37. KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27, 222-224.
38. Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Veelen W, Hoppener JW, and Franklin DS (2007). Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis. Oncogene 26, 554-570.
39. Basu TN, Gutmann DH, Fletcher JA, Glover TW, Collins FS, and Downward J (1992). Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients. Nature 356, 713-715.
40. Bollag G, Clapp DW, Shih S, Adler F, Zhang YY, Thompson P, Lange BJ, Freedman MH, McCormick F, Jacks T, et al. (1996). Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells. Nat Genet 12, 144-148.
41. ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69, 265-273.
42. Kim HA, Ratner N, Roberts TM, and Stiles CD (2001). Schwann cell proliferative responses to cAMP and Nf1 are mediated by cyclin D1. J Neurosci 21, 1110-1116.
43. ras, inhibition of cell proliferation and morphological changes. Oncogene 11, 325-335.
44. Zatyka M, da Silva NF, Clifford SC, Morris MR, Wiesener MS, Eckardt KU, Houlston RS, Richards FM, Latif F, and Maher ER (2002). Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease. Cancer Res 62, 3803-3811.
45. Wykoff CC, Sotiriou C, Cockman ME, Ratcliffe PJ, Maxwell P, Liu E, and Harris AL (2004). Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer 90, 1235-1243.
46. Maandag EC, van der Valk M, Vlaar M, Feltkamp C, O'Brien J, van Roon M, van der Lugt N, Berns A, and te Riele H (1994). Developmental rescue of an embryonic-lethal mutation in the retinoblastoma gene in chimeric mice. EMBO J 13, 4260-4268.
47. Petri BJ, Speel EJ, Korpershoek E, Claessen SM, van Nederveen FH, Giesen V, Dannenberg H, van der Harst E, Dinjens WN, and de Krijger RR (2008). Frequent loss of 17p, but no p53 mutations or protein overexpression in benign and malignant pheochromocytomas. Mod Pathol 21, 407-413.
48. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, and Jacks T (1994). Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Genet 7, 480-484.
49. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, and Weinberg RA (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4, 1-7.
50. Vander Heiden MG, Cantley LC, and Thompson CB (2009). Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033.
51. Favier J, Briere JJ, Burnichon N, Riviere J, Vescovo L, Benit P, Giscos-Douriez I, De Reynies A, Bertherat J, Badoual C, et al. (2009). The Warburg effect is genetically determined in inherited pheochromocytomas. PLoS One 4, e7094.
52. Roe JS and Youn HD (2006). The positive regulation of p53 by the tumor suppressor VHL. Cell Cycle 5, 2054-2056.
53. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, Hurley PJ, Bunz F, and Hwang PM (2006). p53 regulates mitochondrial respiration. Science 312, 1650-1653.
54. Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, and Vousden KH (2006). TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107-120.
55. Lebedeva MA, Eaton JS, and Shadel GS (2009). Loss of p53 causes mitochondrial DNA depletion and altered mitochondrial reactive oxygen species homeostasis. Biochim Biophys Acta 1787, 328-334.